

APR 15 2003

Application No.: 09/905,744

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Sequences which lack SEQ ID NO: tags are disclosed throughout the specification, including pages 95, 98, 100, 101 and 103.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212


PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED
APR 30 2003
TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1644
Docket No. 28110/36120A

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

Applicant(s): Chadwick et al.

Serial No: 09/905,744

Filed: 07/13/2001

For: METHODS AND
COMPOSITIONS
RELATING TO CD39-LIKE
POLYPEPTIDES AND
NUCLEIC ACIDS

Examiner: Amy M. DeCloux

Group: 1644

**CERTIFICATE OF MAILING
UNDER 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop SEQUENCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: April 10, 2003

Name of Person signing Certificate: Donna B. Rose

Signature of Person Mailing

TRANSMITTAL LETTER

Mail Stop SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed are the following items for filing in the above-referenced U.S. Patent Application:

1. Amendment and Response under 37 CFR § 1.111 to Office Action Mailed January 13, 2003 (9 pages);
2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 page);
3. Statement Regarding Sequence Listing under 37 CFR § 1.821(f) and § 1.825(b) (2 pages);
4. Statement under 37 CFR § 1.52(e)(3) (1 page);
5. Paper copy of substitute Sequence Listing (37 pages);
6. CD-ROM Substitute Sequence Listing (2 CD-ROMs); and
7. Return postcard.

Applicants have previously claimed small entity status (See 37 CFR 1.27).

Applicants do not believe that a fee is due for the submission of these papers, however, the Commissioner is hereby authorized to charge payment for any fees which may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 501169. A duplicate copy of this sheet is enclosed.

Please refund any overpayment to Nuvelo at the address below.

Respectfully submitted,

Dated: April 10, 2003

By: Renée S. Polizotto
Renée S. Polizotto, PhD.
Agent for Applicants
Registration No. 53,474
NUVELO
675 Almanor Avenue
Sunnyvale, CA 94085
(408) 215-4000
(408) 524-8145 FAX